Medical technology company iRhythm Technologies (NASDAQ: IRTC) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 20.1% year on year to $224.2 million. The company expects the full year’s revenue to be around $885 million, close to analysts’ estimates. Its non-GAAP profit of $0.58 per share was significantly above analysts’ consensus estimates.

Is now the time to buy IRTC? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

iRhythm’s second quarter results were met with a strong positive market reaction, reflecting the company’s ability to deliver both robust revenue growth and significant margin improvement. Management attributed this performance to sustained demand for the Zio ambulatory cardiac monitoring platform and effective commercial execution across cardiology, primary care, and new healthcare channels. CEO Quentin Blackford noted that the company’s operational discipline and successful integration of digital workflow tools were key factors behind the margin gains, stating that manufacturing automation and workflow optimization contributed to the uplift in gross margin. With new partnerships and expanding reach in both domestic and international markets, iRhythm’s momentum was broad-based this quarter.

Looking forward, iRhythm’s updated guidance is shaped by the pending acquisition of VitalConnect, continued expansion into new care settings, and investments in technology-driven workflow improvements. Management highlighted plans to leverage VitalConnect’s multi-modal monitoring platform to address a wider range of clinical needs and expand into markets such as mobile cardiac telemetry and remote patient monitoring. CFO Dan Wilson emphasized that productivity enhancements from AI-driven tools and further integration into provider workflows are expected to support future profitability, while investments in direct-to-patient initiatives and primary care channels will remain a priority for growth.

Key Insights from Management’s Remarks

Management cited the combination of strong Zio platform demand, operational efficiencies, and new product initiatives as the main drivers behind the quarter’s performance.

• Zio platform drives growth: Broad adoption of iRhythm’s Zio ambulatory cardiac monitoring system remained the primary engine for revenue, with robust uptake in both traditional cardiology and upstream primary care settings. Management pointed to increased integration with electronic health records (EHR) as a driver of efficiency and provider adoption.

• VitalConnect acquisition expands capabilities: The announced agreement to acquire VitalConnect will add a complementary four-in-one cardiac monitoring platform and open access to the entire mobile cardiac telemetry (MCT) market, which management estimates as a $1 billion opportunity. This also accelerates iRhythm’s entry into inpatient and hospital-to-home monitoring segments.

• Margin expansion through automation: Gross margin improvements were achieved via targeted manufacturing automation, workflow optimization, and scale benefits from higher volumes. CEO Quentin Blackford explained that the third-generation algorithm, once deployed, is projected to cut technician review time by up to 50%, supporting further margin gains.

• Innovative channels and partnerships: New agreements—such as those with Lucem for predictive arrhythmia solutions—contributed to rapid growth in the innovative channel, particularly among value-based care and population health partners. Early pilot programs reportedly identified patients with arrhythmias before they entered the diagnostic process.

• Regulatory and operational milestones: The company secured final coverage determinations from major Medicare contractors, mitigating reimbursement uncertainty. Additionally, iRhythm resolved litigation with Baxter and addressed a recent cybersecurity incident without material impact on operations. These developments remove distractions and allow management to focus on growth and integration priorities.

Drivers of Future Performance

Management’s outlook centers on leveraging new product capabilities, expanding in primary care and international markets, and integrating VitalConnect to drive sustainable growth and profitability.

• VitalConnect integration and product expansion: The successful acquisition and integration of VitalConnect is expected to unlock new revenue streams in mobile cardiac telemetry and inpatient monitoring. Management emphasized the importance of offering a portfolio of solutions to address varying physician and patient needs, while also accelerating the company’s roadmap for multi-vital monitoring.

• Continued investment in technology and direct-to-patient initiatives: Ongoing investments in AI-driven workflow tools and direct-to-patient marketing are intended to improve efficiency, enhance patient identification, and support margin expansion. Management noted that early results from these initiatives are promising, and spend is expected to increase in the second half of the year as pilots scale.

• Disciplined cost management and regulatory vigilance: Future profitability will depend on maintaining tight expense control, especially as the company ramps up investments in new channels. Management also identified the resolution of its outstanding FDA warning letter and successful navigation of regulatory reviews as important for sustaining operational momentum.

Catalysts in Upcoming Quarters

In upcoming quarters, the StockStory team will be watching (1) the integration and commercial rollout of VitalConnect’s platform, (2) the effectiveness of direct-to-patient and predictive analytics initiatives in driving new patient referrals, and (3) progress toward FDA clearance for Zio MCT and resolution of the outstanding FDA warning letter. Execution on international expansion and margin improvement from automation will also serve as important signposts of execution.

iRhythm currently trades at $138.66, up from $128.12 just before the earnings. In the wake of this quarter, is it a buy or sell? See for yourself in our full research report (it’s free).

Stocks That Trumped Tariffs

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.